FinancialNewsMedia.com

FinancialNewsMedia.com
Professional News Dissemination Services

Tuesday, September 30, 2014

Tapinator (TAPM) Reaches Milestone of 200,000 New Daily Players

NEW YORK, - (http://www.financialnewsmedia.com News Alert) - Tapinator, Inc. (OTC: TAPM) today announced that its games portfolio has reached the significant milestone of generating over 200,000 new players on a daily basis. This represents an all-time high for the Company in terms of daily new user volume.

These new players are derived from both the Company's recently launched games, such as Ambulance Rescue Simulator and Angry Shark Simulator, as well as the Company's older titles, including Transporter Plane 3D and Bus Driver 3D. Furthermore, the vast majority of these new players are acquired with zero marketing spend, by utilizing the Company's ability to successfully drive its titles up the app store leaderboards through cross promotion and search optimization strategies.

"Reaching 200,000 new daily players is a very significant milestone for us. We will enter Q4 with great new user numbers, and will be favorably positioned to take advantage of the holiday season's higher CPMs and advertising revenue potential," stated Tapinator CEO, Ilya Nikolayev.

To view Tapinator's portfolio, please navigate to the iOS, Google Play, or Amazon App Store and search for "Tapinator." Or, for a full listing of Tapinator games with links to each app store, please go to Tapinator.com.

About Tapinator:

Tapinator (OTC: TAPM) is a global developer and publisher of mobile games on the iOS, Google Play, and Amazon platforms. The Company focuses on operating its own titles, publishing properties where it holds substantial ownership positions, and making strategic investments into promising mobile companies. Tapinator's owned and operated portfolio includes over 55 mobile gaming titles that, collectively, have over 30 million users. A number of these titles have risen to the top of the mobile leaderboard charts and have been featured by the Apple, Google, and Amazon App Stores. Founded in 2013, Tapinator is headquartered in New York, with development offices in Pakistan, Denmark, and Indonesia. For a full listing of Tapinator game titles, please go to Tapinator.com. For further financial information on the Company, please go to OTCMarkets.com/stock/TAPM.  For live updates, please like us on Facebook at facebook.com/Tapinator or follow us on Twitter at twitter.com/Tapinator.

Forward Looking Statements:

To the extent that statements contained in this press release are not descriptions of historical facts regarding Tapinator, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will" "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements regarding the quoting and trading of our common stock and our expectations regarding our development and monetization plans for our mobile games. Forward-looking statements in this release involve substantial risks and uncertainties that could cause the development and monetization of our mobile games, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the hits nature of the mobile gaming business. Tapinator undertakes no obligation to update or revise any forward-looking statements. The quoting and trading of the company's common stock on the OTC Market Group's OTC Link quotation system is often thin and characterized by wide fluctuations in trading prices, due to many factors that may have little to do with the company's operations or business prospects. As a result, there may be volatility in the market price of the shares of the company's common stock for reasons unrelated to operating performance. Moreover, the OTC Market Group's OTC Link quotation system is not a stock exchange, and trading of securities on it is often more sporadic than trading of securities listed on the NASDAQ Stock market or another securities exchange. Accordingly, stockholders may have difficulty reselling any of their shares. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Tapinator's filings with the OTC Market Group, which are available through http://www.otcmarkets.com.

CONTACT:

Tapinator Investor Relations
investor.relations@tapinator.com
+1-914-930-6232

SOURCE Tapinator, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which iis a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated one thousand seven hundred dollars for Tapinator, Inc. news coverage by the company.  FNMG HOLDS NO SHARES OF Tapinator, Inc.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Wednesday, September 24, 2014

ETST Announces Live CEO Interview and Recent Growth Progress as an Emerging Company Delivering Cutting Edge Nutraceuticals, Bioceuticals and Dietary Supplements for the Health, Wellness, Sports and Alternative Medicine Markets

BOCA RATON, FL, - (http://www.financialnewsmedia.com News Alert) - Earth Science Tech, Inc. (OTCQB: ETST) ("ETST" or "the Company"), a unique biotechnology company focused on nutraceuticals, bioceuticals and dietary supplements, announced today that its CEO, Harvey Katz PhD, as well as the company, was featured in a live video and article done by the Cannabis Financial Network. This new coverage and live CEO interview featured by Cannabis Financial Network outlines the recent success ETST has made in rapidly growing and expanding its business as an emerging company on many fronts. Some of the featured highlights from this live CEO video and article on ETST include:

-  ETST received two large bulk shipments of non-psychoactive, food-grade,
    CBD-enriched hemp oil, which is completely legal in 50 states and over
    40 countries worldwide (as per U.S. Hemp Foods specifications).
-  ETST already began selling; shipping its High Grade CBD Rich Hemp oil
    and an initial order to an outlet in Fort Lauderdale and its management
    is working hard to drum up additional supply lines.
-  ETST is moving towards widespread commercialization while setting
    themselves up to be a high-volume throughput channel for high-grade CBD.
-  ETST has already begun making their CBD products available online in
    half-ounce, ounce and two ounce bottles, and has made sizeable
    investments into their high-volume inventory model, with hundreds of
    thousands of dollars already outlaid and ambitions to fill persistent
    supply constraints in the CBD.
-  ETST funded assistant dean of the University of Central Oklahoma's
    College of Mathematics and Science, Wei R. Chen, Ph.D., with a $10k
    grant to study the anti-tumor effects of its ETST Hemp oil enriched with
    CBD on cancer cells, pushing the boundaries of the established anti-
    tumor properties of CBD.
-  ETST is developing a variety of nutraceuticals, bioceuticals and dietary
    supplements for health, wellness, sports and alternative medicine, as
    well as natural alternatives to prescription medications, both CBD and
    non-CBD based.
-  ETST has developed a unique menopause and perimenopause formula for
    aging women known as ProgesteBeauty(TM), and the company is currently in
    the process of opening the first retail location for their wholly-owned
    Nutrition Empire, Inc. subsidiary in an upscale area of Coral Gables,
    Florida. The retail footprint will help support product roll outs and
    the company will also be working to dovetail their overall commercial
    presence with key strategic partners and third party resellers who
    already control chunks of the nutritional and supplement markets.
-  ETST has secured a lease for their initial retail location, which is
    situated right on the edge of the University of Miami campus, on the
    first floor of a luxury apartment complex, that stipulates no other
    nutrition or supplement store will be located within a three-mile
    radius. This will also be the first retail store in all of Dade County
    where consumers can walk right in and buy CBD oil over the counter, as
    well as get their hands on ProgesteBeauty, or the company's soon-to-be-
    released, oxygen-based colon cleanser with probiotics (L. rhamnosus and
    L. acidophilus), OxyBiotic(TM).
-  ETST goal is to have around 600 best-in-class health and wellness
    products in-store, as well as a terminal for customers to order products
    for next-day delivery, again emphasizing ready supply as a key brand
    hallmark.


ETST is happy to see that the Cannabis Financial Network has taken notice that ETST is an emerging company delivering cutting edge Nutraceuticals, Bioceuticals and Dietary Supplements designed for excellence in the areas of Health, Wellness, Sports and Alternative Medicine. This also includes that fact that ETST looks to help improve the quality of life for Consumers Worldwide through the use of such products. ETST is also dedicated to providing Natural Alternatives to prescription medications through Nutritional Supplements and Dietary Supplements that help improve common disorders and illnesses. To read the coverage and article featured by the Cannabis Financial Network on ETST see below.
Earth Science Tech Brings High Grade CBD To 50 States Via Volume Inventory Model

Cannabis Financial Network / Whitefish, MT / By now nearly everyone has heard of the case of Charlotte Figi, a seven-year-old girl with Dravet Syndrome (a form of severe and intractable epilepsy), who was having as many as 50 seizures a day. In desperation, Charlotte's parents tried everything pharmaceutical science could throw at the problem, even debilitating drugs like barbiturates and benzodiazepines, in an ultimately futile attempt to curb the devastation. The father finally took the leap to try a low-THC (Tetrahydrocannabinol, the psychoactive component), CBD-rich (Cannabidiol) strain of medical marijuana known as Charlotte's Web and since dosing, his daughter has truly thrived, with only two to three seizures per month and a much-improved overall condition. A groundbreaking clinical trial is coming up to study Charlotte's Web in Dravet Syndrome at the University of Colorado and this study's results could provide a real boost to the CBD, as well as broader, medical marijuana markets.

The CBD market in particular has been growing by leaps and bounds in recent years, with heavy-hitters like GW Pharmaceuticals (GWPH) already seeing good traction on their Multiple Sclerosis treatment, Sativex(r), which clearly benefits a great deal from CBD's increasingly apparent pain-relieving, anti-inflammatory, and immunodulatory effects. Smaller players like CannaVEST Corp. (CANV) are finding the market wide open too and CannaVEST has managed to establish a considerable CBD supply business, while also working on a range of industrial hemp-derived CBD nutraceuticals. Industrial hemp is widely known for its low THC levels and comparatively higher levels of CBD, making it an ideal source for developing health and wellness products intended to treat a whole host of conditions, from chronic pain and epilepsy, to diabetes. Even various neurological disorders like ADHD and Parkinson's disease are among the immediate prospects for CBD-rich offerings, according to Project CBD.

CBD has even been shown to promote nutritional health in aging people, acting as an antioxidant and neuroprotectant, superbly suited to age-related inflammatory and autoimmune diseases. Pair the 10,000-plus Baby Boomers retiring per day (Pew Research) and Research and Markets' latest report on the U.S. nutraceutical market indicating a projected 6% CAGR through 2017, as the space swells to some $75.3B or more, and you get a perfect storm for CBD nutraceuticals.

Ready-Supply Inventory Model, Maximum Distribution Potential

One of the more compelling plays in the space today is Earth Science Tech, Inc. (ETST), which recently received its first two shipments of non-psychoactive, food-grade, CBD-enriched hemp oil, which is completely legal in 50 states and over 40 countries worldwide (as per U.S. Hemp Foods specifications). With over 50 liters from their first two shipments, an initial order already out the door to an outlet in Fort Lauderdale and management working hard to drum up additional supply lines, Earth Science Tech is rapidly moving towards widespread commercialization while setting themselves up to be a high-volume throughput channel for high-grade CBD. Perhaps more importantly, management is steadfastly committed to genuinely helping consumers get the best nutrition and dosing information possible, as well as creating shareholder upside. This was clearly demonstrated by the CEO in a recent video interview with leading cannabis investment news source, CannabisFN, when he said a salary won't be pursued until he knows the company is doing well.

CannabisFN Executive Interview | Earth Science Tech (ETST) from TDM Financial on Vimeo.

Earth Science Tech has already begun making their CBD products available online in half-ounce, ounce and two ounce bottles, and has made sizeable investments into their high-volume inventory model, with hundreds of thousands of dollars already outlaid and ambitions to fill persistent supply constraints in the CBD market via a steady stream of readily available product. Earth Science Tech has even funded assistant dean of the University of Central Oklahoma's College of Mathematics and Science, Wei R. Chen, Ph.D., with a $10k grant to study the anti-tumor effects of the such hemp oil enriched with CBD on cancer cells, pushing the boundaries of the established anti-tumor properties of CBD. Dr. Chen brings an impressive track record of over two decades in cancer research to the project as its lead and has noted that the project may result in a new understanding of the potential applications of this non-toxic and largely beneficial natural product.

Developing Nutraceutical Portfolio, Retail Footprint

Beyond raw CBD enriched hemp oil, Earth Science Tech is seeking to develop a variety of nutraceuticals, bioceuticals and dietary supplements for health, wellness, sports and alternative medicine, as well as natural alternatives to prescription medications, both CBD and non-CBD based. This is the same model employed to great success by companies like LifeVantage Corp. (LFVN), which notably cropped out into sports nutrition recently, extending their reach from a strong base in nutraceutical dietary supplements.

Earth Science Tech has developed a unique menopause and perimenopause formula for aging women known as ProgesteBeauty(TM), and the company is currently in the process of opening the first retail location for their wholly-owned Nutrition Empire, Inc. subsidiary in an upscale area of Coral Gables, Florida. The retail footprint will help support product roll outs and the company will also be working to dovetail their overall commercial presence with key strategic partners and third party resellers who already control chunks of the nutritional and supplement markets. Earth Science Tech has secured a lease for their initial retail location, which is situated right on the edge of the University of Miami campus, on the first floor of a luxury apartment complex, that stipulates no other nutrition or supplement store will be located within a three-mile radius. The location is right by a 24k square foot gourmet grocery store as well, in a premier shopping district with loads of foot traffic. This will also be the first retail store in all of Dade County where consumers can walk right in and buy CBD oil over the counter, as well as get their hands on ProgesteBeauty, or the company's soon-to-be-released, oxygen-based colon cleanser with probiotics (L. rhamnosus and L. acidophilus), OxyBiotic(TM). The goal is to have around 600 best-in-class health and wellness products in-store, as well as a terminal for customers to order products for next-day delivery, again emphasizing ready supply as a key brand hallmark.

Spartan Management Leveraging Top Consultants

Unlike many other companies in a similar position, which might tend to bloat the management team with a lot of extraneous personnel in order to try and cover all their bases, ETST has opted to create a lean and mean management team, tapping the best of the best in requisite fields to act as consultants. By maintaining a network of top-quality consultants, the kind of expert formulators responsible for the company's ProgesteBeauty and OxyBiotic formulas, ETST aims to keep management expenses down and yet remain highly competitive in the space.

For More Information Visit Earth Sciences Company Website: http://www.earthsciencetech.com/.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.

SOURCE: Emerging Growth LLC

ETST is proud to offer the finest, most natural and consistent High Grade CBD Rich Hemp Oil with no fillers, preservatives or additives. The company's CBD Rich Hemp Oil is made for consumers who want the highest quality natural CBD. ETST High Grade CBD (Cannabidiol) Rich Hemp Oil is natural and formulated using a wide array of cutting-edge technologies such as super critical extraction, isolation, and micron filtration. It is lab tested multiple times during the manufacturing process, from seed to shelf. This also includes being tested for CBD content, other Cannabinoid content, yeast/mold/fungus, and bacteria like E. coli to ensure safety and top quality. Cannabidiol (CBD) is a naturally occurring constituent of the hemp plant (seed, stem and stalk). It is the most abundant non-psychoactive cannabinoid in hemp (cannabis), and is commonly used as a dietary supplement to support general health, immune system support, nervous system and much more. Research shows that many scientists and doctors think the cannabinoids work synergistically to support the whole human endo-cannabinoid system (internal and natural human cannabinoid system). Furthermore, many scientists and doctors believe the endo-cannabinoid system plays a fundamental role in the functioning of many of the major human physiological systems, including the immune and nervous systems.

ETST is capable of supplying and offering its High Grade CBD Rich Hemp Oil in all 50 states and over 40 countries as a nutritional and dietary supplement designed to support overall health and wellness.

ETST invites all interested parties to contact the company directly at info@earthsciencetech.com in regards to securing its All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil for wholesale, resale, private labeling or distribution. ETST is open to forming new strategic partnerships, joint ventures and/or supplying vendors, resellers and third party distribution companies with its High Grade CBD Rich Hemp Oil at wholesale prices in order to better help supply the health and wellness markets on a large scale. The company feels it can grow at a much faster pace by focusing on becoming a large wholesale distributor of its High Grade CBD Rich Hemp Oil and by aligning itself with key strategic partners and third party resellers that are already well diversified in the Health and Wellness markets. ETST's High Grade CBD Rich Hemp Oil is All Natural and derived completely from the federally legal industrial hemp plant. Industrial Hemp (Hemp) is not marijuana and will not get you 'high' and it does not require a medical license of any kind to authorize purchase. Hemp oil contains CBD -- a non-psychoactive compound of the plant. There are millions of hemp oil consumers around the world and this number is rapidly rising with an increasing number of reports and studies showing a variety of benefits of hemp oil. ETST is now offering the availability for the Health and Wellness markets, consumers and its shareholders to try its All Natural High Grade CBD Rich Hemp Oil in small quantities at wholesale prices online at http://www.earthsciencetech.com/cbd-rich-hemp-oil/.

ABOUT ETST: ETST is a unique Biotechnology company focused on delivering cutting edge Nutraceuticals, Bioceuticals and Dietary Supplements designed for excellence in the areas of Health, Wellness, Sports and Alternative Medicine and to improving the quality of life for Consumers Worldwide. ETST is also dedicated to providing Natural Alternatives to prescription medications through Nutritional Supplements and Dietary Supplements that help improve common disorders and illnesses. This may include products such as CBD (Cannabidiol) as a natural constituent of Hemp Oil, Vitamins, Minerals, Herbs, Botanicals, Personal Care Products, Homeopathies, Functional Foods and other products. These products may be in various formulations and delivery systems including (but not limited to) capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs.

ETST is focused on researching and developing innovative Hemp extracts and to make them accessible Worldwide. ETST plans to be the premier supplier of the highest quality Hemp Oil Enriched with High Grade CBD (Cannabidiol). ETST primary goal is to advance different High Quality Hemp extracts with a broad profile of Cannabinoids and additional natural molecules found in Industrial Hemp and to identify their distinct properties. The company is dedicated in offering its consumers the finest and purest quality All Natural CBD Rich Hemp oil while never compromising on quality. This High Grade CBD (Cannabidiol) Rich Hemp oil is classified as "food based" and therefore perfectly permissible in all 50 states and more than 40 countries. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD possesses no psychoactive qualities and presents a continuing stream of overwhelming evidence of significant Health and Wellness benefits. With no psychoactive ingredient, CBD is a ready-for-market Hemp-based Nutraceutical. According to scientific and clinical studies, CBD has the potential to help a range of conditions including epilepsy, diabetes, rheumatoid arthritis, chronic pain, alcoholism, schizophrenia, PTSD, antibiotic-resistant infections, and various neurological disorders (Source: National Center for Biotechnology Information http://www.ncbi.nlm.nih.gov). CBD has moreover exhibited Neurogenic and Neuroprotective effects and its anti-cancer properties are currently being investigated at several academic research centers in the United States and abroad. The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be "food based" and therefore saleable. These new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach and available to consumers in all 50 states and in more than 40 countries. CBD (cannabidiol), a naturally occurring constituent of the industrial hemp plant, promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 "Cannabinoids as antioxidants and neuroprotectants."

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

FORWARD LOOKING DISCLAIMER: This release contains forward-looking statements that involve risks and uncertainties. Readers are referred to the Securities and Exchange Commission filings filed by the Company on EDGAR at http://www.sec.gov/edgar.shtml, specifically the most recent reports which identify important risk facts that could cause actual results to differ from those contained in the forward-looking statements. The Company undertakes no obligation to review or confirm analysts' expectations or estimates or to publicly release any revisions to any forward-looking statements. The information contained in this press release should not be construed as any indication of the Company's future stock price, its revenues or results of operations.

Embedded Video Available: http://vimeo.com/106424035

Contact:
Earth Science Tech, Inc.
Phone: +1(561) 705-1278

SOURCE: Earth Science Tech, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated one thousand six hundred dollars for Earth Science Tech, Inc. news coverage by the Company.  FNMG HOLDS NO SHARES OF Earth Science Tech, Inc.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Tuesday, September 23, 2014

RiceBran Technologies Enters the Personal Care and Nutricosmetics Markets with a Series of Newly Developed Rice Bran Based Products

New products developed at Healthy Natural subsidiary capitalize on unique composition of rice bran, rice bran oil and rice bran derivatives to protect and maintain skin health

SCOTTSDALE, Ariz., - (http://www.financialnewsmedia.com News Alert) - RiceBran Technologies (NASDAQ: RIBT) and (RIBTW) (the "Company" or "RBT"), a global leader in the production and marketing of value added products derived from rice bran, today announced completion of the development of a series of new rice bran-based finished products targeting the personal care and nutricosmetics markets. 

In collaboration with new and existing customers, the Company has developed its initial cosmetics and personal care product offerings using rice bran and derivatives produced in its USA Segment plants, as well as rice bran oil manufactured at its Irgovel facility in Pelotas, Brazil.

The new rice bran-based products, which include hand and skin creams, anti-aging serum, exfoliants, moisturizers, and other treatments, were formulated at the Company's Healthy Natural facility in Irving, Texas. Healthy Natural's management team has extensive experience formulating and manufacturing natural products-based cosmetics and personal care products for the retail and direct-to-consumer markets, and has been developing products targeting the personal care and cosmetics markets for more than 20 years. 

These new product offerings will be sold as private label finished products on a business-to-business basis. RiceBran Tehnologies is in active discussions with a number of potential partners to launch its products through a variety of distribution channels and expects the initial products to reach consumers in the fourth quarter of 2014 and the first quarter of 2015.

Mark McKnight, Senior Vice President of Contract Manufacturing at RiceBran Technologies, commented, "During the last decade, the natural products industry has seen nutritional ingredients rich in anti-oxidants and other micronutrients migrate into cosmetics and personal care formulas, creating an emerging "nutricosmetics" marketplace. Rice bran contains many high value ingredients, including gamma oryzanols, ceramides, vitamin E and UV absorbing compounds that help protect and maintain skin health by promoting hydration and elasticity.  We see our newly launched rice bran-based products as a perfect fit for this multi-billion dollar market opportunity."

CEO & President W. John Short commented, "Rice bran has a long history of inclusion in beauty products in Japan and other Asian markets. In fact, one of the greatest compliments a Japanese woman can be given is to be called a "rice bran beauty" or Nuka Bijin. When we made the decision to acquire Healthy Natural, we believed that the addition of superior formulation capabilities would not only further our market penetration in nutritional and functional foods but would also enable us to move into other high growth areas such as the nutricosmetics and personal care markets. With this launch, we are taking a major step forward in that direction. This represents a significant revenue growth opportunity for our Company in 2015 and for many years to come."

RiceBran Technologies is a human food ingredient and animal nutrition company focused on the procurement, bio-refining and marketing of numerous products derived from rice bran. Rice Bran Technologies has proprietary and patented intellectual property that allows us to convert rice bran, one of the world's most underutilized food sources, into a number of highly nutritious human food ingredient and animal nutrition products. Our target markets are human food ingredients and animal nutrition manufacturers and retailers, as well as natural food, functional food and nutraceutical supplement manufacturers and retailers, both domestically and internationally. More information can be found in our filings with the SEC and by visiting our website at www.ricebrantech.com.

Forward-Looking Statements

This release contains forward-looking statements, including, but not limited to, statements about RiceBran Technologies' expectations regarding opportunities in the cosmetics. These statements are made based upon current expectations that are subject to known and unknown risks and uncertainties.  RiceBran Technologies does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information.  Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in RiceBran Technologies' filings with the Securities and Exchange Commission, including its most recent periodic reports. 

Investor Contact

Ascendant Partners, LLC
Fred Sommer
+1-732-410-9810
fred@ascendantpartnersllc.com

SOURCE RiceBran Technologies

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated one thousand six hundred dollars for RiceBran Technologies news coverage by the Company.  FNMG HOLDS NO SHARES OF RiceBran Technologies.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Friday, September 19, 2014

Pressure BioSciences Announces Completion of the First Phase of Its Commercialization Plan for the Barozyme HT48, the Company's Recently Released High Throughput PCT-based Instrument System

The Company Expects to Build and Ship Nine Instrument Systems for Evaluation between Mid-October and Late November. The Company Believes One or More Systems will be Purchased by the Evaluating Laboratories, Impacting Q4 2014 Revenue

SOUTH EASTON, Mass., - (http://www.financialnewsmedia.com News Alert) - Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced it has received and approved all parts required to build nine high throughput Barozyme HT48 instruments and has begun to manufacture the new PCT-based instrument system. The Company believes the first instrument will be ready for shipment by mid-October and that additional Barozyme instruments will be built and released at a rate of about one per week thereafter.

The bench-top Barozyme HT48 is a first-in-class, high throughput PCT-based instrument. It is capable of processing up to 48 samples simultaneously using the Company's new and proprietary BaroFlex 8-well processing strips. The BaroFlex strips were designed and manufactured to the industry-standard micro-titer plate format, which the Company believes will allow the new Barozyme HT48 system to seamlessly integrate with the automated, standardized, high throughput liquid handling robotic and analytical systems installed in tens of thousands of biological research laboratories worldwide.

Dr. Nathan P. Lawrence, Vice President of Marketing and Sales, said: "the Barozyme HT48 was specifically designed for rapid, high quality enzymatic digestion of proteins, a universally important procedure conducted in thousands of laboratories worldwide. The ability of the Barozyme HT48 to process up to 48 samples simultaneously in a "microplate" format is a major improvement in the ergonomics of sample handling and a key step towards automation of PCT-based biological sample preparation. The new BaroFlex format of disposable sample containers in strips of eight processing wells not only lowers the total cost per sample processed by PCT but improves the sample handling and user experience. Lastly, the Barozyme HT48's flexible computer control was designed with GLP compliance in mind to meet specific demands of biopharmaceutical quality control and clinical proteomics."

Mr. Richard T. Schumacher, President and CEO, said: "With a growing list of potential customers and strategic partners interested in evaluating the Barozyme HT48, our number one priority over the past three months has been to focus on the manufacture of the initial build of instrument systems, with a target of having commercial-grade instruments and consumables available for evaluation by this fall. I am pleased to report that we are on schedule to meet that target."

Mr. Schumacher continued: "We gave guidance earlier this year to not expect the sale of Barozyme HT48 instruments in 2014. However, based on discussions with existing customers (such as one who asked to evaluate the Barozyme HT48 ASAP because the number of samples they routinely process by PCT "was exploding") we are changing that guidance. We now believe that the evaluation period required by some existing customers will be shorter than first thought, and that one or more existing customers will ask to purchase the instrument shortly after their evaluation concludes. Based on this and other indications, we continue to believe that the Barozyme HT48 system is a 'game-changer' for PBI."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.

Forward Looking Statements

Statements contained in this press release regarding PBI's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2013, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter

Investor Contacts: Richard T. Schumacher, President and CEO Nathan P. Lawrence, Vice President, Marketing and Sales (508) 230-1828 (T)

SOURCE Pressure BioSciences, Inc.


FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated one thousand five hundred dollars for Pressure BioSciences, Inc. news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF Pressure BioSciences, Inc.

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not

GenSpera (GNSZ) Wins Summary Judgment in Mhaka Litigation

SAN ANTONIO, Texas, - (http://www.financialnewsmedia.com News Alert) - GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States District Court for the District of Maryland has granted the company's summary judgment with respect to all pending claims asserted against it by Annastasiah Mhaka.

"We welcome the court's decision and are pleased with the result," said Craig Dionne, GenSpera's CEO. "We believe that our defense against these claims has demonstrated GenSpera's commitment to protecting its technologies and intellectual property portfolio." 

As previously announced in the company's public filings, on March 12, 2012, as a result of certain allegations made by Ms. Mhaka, GenSpera instituted a declaratory judgment action against Annastasiah Mhaka in the United States District Court for the District of Maryland: GenSpera, Inc. v. Mhaka, Civil Action No. MJG-12-772 (D. Md.) seeking a declaratory judgment that Ms. Mhaka should not be added as an inventor to either the US 7,468,354 patent or the US 7,767,648 patent (the '354 patent and '648 patents) (the first of which claims the company's proprietary PSMA-activated lead drug candidate, mipsagargin, and the latter of which claims methods of use of mipsagargin). On May 1, 2013, the Court granted GenSpera's motion for summary judgment and issued a declaratory judgment establishing that Ms. Mhaka should not be added to the two patents under 35 U.S.C. $ 256.

As part of the litigation, Ms. Mhaka made certain counterclaims against GenSpera, along with Drs. Samuel Denmeade and John Isaacs (two of the company's co-founders), based on allegations that she had been wrongly omitted from the '354 patent and '648 patent. On January 2, 2014, Drs. Isaacs and Denmeade moved for summary judgment, and GenSpera joined in the motion. On May 6, 2014, GenSpera moved separately for summary judgment, a motion that Drs. Denmeade and Isaacs joined in part. 

On September 12, 2014, the Court granted GenSpera's motion for summary judgment as well as the motion for summary judgment filed by Drs. Denmeade and Isaacs.  Judgment in favor of GenSpera, Dr. Isaacs, and Dr. Denmeade was entered concurrently. 

About GenSpera

GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is therefore expected to have potential efficacy in a wide variety of tumor types.

Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma (liver cancer) and glioblastoma patients (brain cancer).

For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.

Company presentations are available at: http://www.genspera.com/

Watch the Corporate Video:

http://youtu.be/jULjEul-mBk


Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

CONTACT:                

Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.  +1(210) 479-8112

Investor Relations: 
Steve Gersten
Capital Markets Group
Steve@CapMarketsGroup.com
+1-813-926-8920

Media:
Dawn Van Zant
(800) 665 0411

SOURCE GenSpera, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated one thousand five hundred dollars for GenSpera, Inc news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF GenSpera, Inc  This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.  

Monday, September 15, 2014

Boreal Water Collection Completes $24 Million Private Label Agreement in Asia with SOHO Corp and Receives First Order for its Catskill Mountain Spring Water Under the Brand Name CATSKY

Global Bottled Water Market Reached Over $157 Billion in 2013

KIAMESHA LAKE, N.Y., - (http://www.financialnewsmedia.com News Alert) - Boreal Water Collection, Inc. (OTC: BRWC) a high end private label bottled water company from NY, announced today that it has completed a $24 million private label agreement with SOHO Corp. for the Asian Market and received from them the first order for Boreal's Catskill Mountain Spring Water under the brand name CATSKY. Recently we have announced that SOHO Corp. has received all the necessary approvals from the Chinese government to import "Boreal's Water" product in large quantities. The total value of this agreement is approximately $24M over a 36 month period.

According to a new report by Transparency Market Research, China is the most active market worldwide for bottled water. Asia Pacific dominated the global bottled water market and accounted for 33% of the global demand valued at approximately $157.27 Billion in 2013. In the coming six years, Asia Pacific is expected to remain the most promising market, with an estimated compound annual growth rate of 10.5% in terms of revenue from 2014 to 2020. The market is expected to reach $279.65 billion by 2020.

"We are very exciting to start our new business, and looking forward to a long term partner with your company Boreal. We hope in the future we can have big successful business in China with the Catsky bottled water" Mr. Peter Cao Yi, General Manager of Jiangsu SOHO International Group Corp.

"We are so pleased with this private label agreement with SOHO Corp. and very happy to receive this new order from China. Asia is a huge market for our products. SOHO Corp. is a major player in Asia and they will promote the CATSKY brand for which the natural spring water comes from our Catskill Mountains spring. We strongly believe that this strategic alliance will help us penetrate this large Asian market earlier than expected and generate profits for our loyal shareholders in our 2015 forecast of revenues." Stated Francine Lavoie, CEO of Boreal Water Collection, Inc..

About Jiangsu SOHO International Group Corp. a/k/a SOHO Corp.

Jiangsu SOHO International Group Corp. a/k/a SOHO Corp., is a multi-billion dollar China-based company originally founded in October 1979. SOHO' s registered capital is 352.8 million Yuan; the net asset is 2 billion Yuan; the total asset is 5 billion Yuan. The total imports and exports of a year reach 1.1 billion dollars, and the sales revenue exceeds 10 billion Yuan. Its main businesses include import and export trade, domestic trade, industrial investment and brand management. www.meetsoho.com

About Boreal Water Collection, Inc.

Boreal Water Collection is a personalized bottler of a full and diverse line of various types of water including:

Functional Enhanced Water - Infused Water - Carbonated Water - Vitamins Enhanced Water - Flavored Still or Sparkling - Minerals Enhanced Water - Oxygenated Water - Electrolyte Water - Distilled Water - Alkaline Water - Caffeinated Water - Natural Spring Water

Boreal provides premium custom bottled water for its clients and customers, whether it is for publicity, promotion, marketing, internal use or a specific event. Boreal also offers fully integrated turnkey service, with prize-winning Boreal private label water, made-to-order labeling, along with distinctive water containers. Current and past customers include Ritz Carlton, Tommy Hilfiger, Saks Fifth Ave, Infiniti, Guess, LaCosta, Porsche, Re/Max, BMW Balance Water, Wa-taah Water, Fred Water, Dean & DeLuca, the Quin Hotel, WestHouse New York, the Surrey New York City, Bouchon Bakery, Princeton University and 3M. Unlike its competitors, Boreal has exclusive access to two pristine and abundant springs, one an award-winning source deep in the untouched wilds of Canada, and the other in the prestigious Catskill Mountains region in New York State. With exclusive unlimited exploitation rights, Boreal has a confirmed volume in excess of thousands of millions of gallons.

For more information on Boreal Water Collection, please contact us by email at: investors@borealwater.com, sales@borealwater.com, or follow us at www.borealwater.com and on the different social media sites such as www.facebook.com/privatelabelbottledwater and www.linkedin.com/in/borealwater.

Safe Harbor for Forward-Looking Statements:

This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact Information

Boreal Water Collectioninvestors@borealwater.comwww.borealwater.com+1-845-794-0400

SOURCE Boreal Water Collection, Inc.

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated two thousand two hundred dollars for news coverage of the current press release issued by Boreal Water Collection, Inc. by a non-affiliated third party.
 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Thursday, September 4, 2014

GenSpera Announces Generic Name "Mipsagargin" for Lead Drug Candidate G-202 per Recommendation by World Health Organization

Mipsagargin Contains New Pre-Stem "Gargin," Defining a Unique Pharmacologic Group Unlike Any Drug Currently or Previously on the Market

SAN ANTONIO, - (http://www.financialnewsmedia.com News Alert) - GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the World Health Organization's (WHO) International Nonproprietary Name (INN) group has recommended the generic name "mipsagargin" (mip sa gar' jin) for its lead drug candidate, also known as G-202, currently in Phase II clinical trials for hepatocellular carcinoma (liver cancer) and glioblastoma (brain cancer). Mipsagargin was also recommended by the United States Adopted Names Council (USAN) of the American Medical Association.

Craig Dionne, PhD, GenSpera's CEO, spoke to the significance of this issuance, "We are pleased that the INN division of WHO and the USAN Council recognized the unique nature of mipsagargin by affording it the new suffix, or pre-stem, of "gargin." The WHO issues approximately 160 name recommendations per year with only 1-2% having new suffixes. New suffixes are generally given to compounds with a unique mechanism of action or structure and serve to define such compound as the first in a possible new class of pharmacological agents. We believe mipsagargin's name recommendation is the result of G-202's novel nature and our innovative approaches to cancer therapy."

GenSpera recently released interim results from the Phase Ib and ongoing Phase II study in hepatocellular carcinoma (HCC) patients who had previously progressed on, or who were intolerant of sorafenib. Data showed 80% of patients treated with mipsagargin had stable disease (no tumor growth) at two months and 50% of patients exhibited stable disease at four months on study. In addition, imaging analysis demonstrated an impressive blockade of tumor blood flow in the single patient evaluated by this method to date.

About Nonproprietary Names

Obtaining a nonproprietary (generic) name is a required part of bringing a new drug to market. The generic names of pharmacologically-related substances demonstrate their relationship by using a common "stem". Using common stems, medical practitioners, pharmacists, or people dealing with pharmaceutical products are able to recognize that the substance belongs to a group of substances having similar pharmacological activity. The generic name mipsagargin includes a novel pre-stem, "gargin," indicating that it is unlike any named drug currently or previously on the market or in development. The pre-stem "gargin" may become an established stem over time, usually as other later developed drugs are recognized to be related in structure or activity to mipsagargin.

Each International Nonproprietary Name is a unique name that is globally recognized and is public property.

About GenSpera

GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is therefore expected to have potential efficacy in a wide variety of tumor types.

Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients.

For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.

Company presentations are available at: http://www.genspera.com

Watch the Corporate Video: http://youtu.be/jULjEul-mBk

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

CONTACT:

Company: Craig Dionne, PhD, CEO GenSpera, Inc. +1-210-479-8112 Investor Relations: Steve GerstenCapital Markets GroupSteve@CapMarketsGroup.com+1-813-926-8920

Media: Dawn Van Zant800-665-0411

SOURCE GenSpera


Disclaimer
FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNMG is NOT affiliated in any manner with any company mentioned herein. FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG was compensated one thousand five hundred dollars for GenSpera, Inc news coverage by a non-affiliated third party.  FNMG HOLDS NO SHARES OF GenSpera, Inc

 This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.